The global demand for Indian generic medicines continues to surge in 2026, driven by India's position as the "Pharmacy of the World" — supplying over 20% of the world's generic…
Indian pharmaceutical companies are executing a strategic pivot in 2026 — doubling down on specialty drugs and biosimilars through record-breaking M&A and US investment, while maintaining their core generics business…
When buying generic medicines from India, verifying the quality and authenticity of the products is paramount. Unlike brand-name drugs, generics rely on documented evidence of bioequivalence, Good Manufacturing Practices (GMP),…
The Indian pharmaceutical sector enters the second half of 2026 with significant momentum as three major developments converge: the India-UK Comprehensive Economic Trade Agreement (CETA) taking effect on July 15,…